|
Short Oral Communications
Day-at-a-glance:
Saturday Sunday
Monday Tuesday
Wednesday
Overview
Timetable [PDF]
Short Orals
1 Basic Short Orals 1 Clinical Short
Orals 2 Basic Short Orals 2
Clinical |
| |
| Monday 7 May, 2007 |
16:30-
17:30 |
 |
Short Oral Communications 1: BASIC
Chairs: Bo Abrahamsen (Copenhagen, Denmark)
Pierre Marie (Paris, France) |
|
| 16:30 |
P001-S |
OSTEOCLASTS SECRETE NON-BONE DERIVED SIGNALS THAT INDUCE
BONE NODULE FORMATION
K. Henriksen*1, A. V. Neutzsky-Wulff1, C. Christiansen2, T. J. Martin3,
M. A. Karsdal1
1Pharmacology, Nordic Bioscience, Herlev, 2Center for Clinical and
Basic Research, Ballerup, Denmark, 3 St. Vincent’s Institute
of Medical Research, Melbourne, Australia |
|
| 16:35 |
P002-M |
LOSS OF ANION EXCHANGER 2 IN MICE RESULTS IN OSTEOPETROTIC
LONG BONES, WHEREAS SKULL IS NOT AFFECTED
I. D. Jansen*1, T. J. de Vries1, J. Ravesloot2, V. Everts1, R. P.
Oude Elferink3
1Periodontology and Oral Cell Biology, ACTA, 2Physiology, 3AMC Liver
Center, Academic Medical Center, Amsterdam, Netherlands |
|
| 16:40 |
P003-T |
CLC-7 CHLORIDE CHANNEL EXPRESSION IS RATE LIMITING
FOR THE RESORPTIVE ACTIVITY OF OSTEOCLASTS
U. Kornak*1, J. C. Fuhrmann2, C. Supanchart1, L. Wartosch2, J. Kuehnisch1,
S. Mundlos1, T. J. Jentsch2
1Institute for Medical Genetics, Charité University Hospital,
2Labor für Medizinische Genomforschung, FMP/Max Delbrueck Centrum,
Berlin, Germany |
|
| 16:45 |
P004-S |
THE EXTRACELLULAR MATRIX (ECM) COMPONENT PRELP
(PROLINE/ARGININE-RICH END LEUCINE-RICH REPEAT PROTEIN) INHIBITS
OSTEOCLASTOGENESIS
M. Alamanou1, N. Rucci1, A. Rufo1, D. Heinegård2, A. Teti*1
1Dept. of Experimental Medicine, University of l’Aquila, l’Aquila,
Italy, 2Dept. of Experimental Medical Science, Lund University,
Lund, Sweden
|
|
| 16:50 |
P005-M |
DIRECT RAB11-RAC1 INTERACTION REGULATES
EXIT OF RECYCLING VESICLES FROM THE PERINUCLEAR COMPARTMENT IS INVOLVED
IN CELLULAR MIGRATION
Y. Sun*1, B. G. Kalman1, H. K. Väänänen1
1Department of Anatomy, Institute of Biomedicine, University of Turku,
Turku, Finland |
|
| 16:55 |
P006-T |
CATHEPSIN K INHIBITORS PREVENT MATRIX-DERIVED
GROWTH FACTOR
DEGRADATION BY HUMAN OSTEOCLASTS
K. Fuller1, K. M. Lawrence1, J. L. Ross1, U. B. Grabowska2, M. Shiroo2,
B. Samuelsson2, T. J. Chambers*1
1Cellular Pathology, St Georges, University of London, London, 2,
Medivir UK, Little Chesterford, United Kingdom |
|
| 17:00 |
P007-S |
SRC MEDIATED CBL-PI3KINASE INTERACTION
REQUIRED FOR OSTEOCLAST FUNCTION
A. Sanjay*1, W. Horne2, R. Baron2
1Anatomy and Cell Biology, Temple University, Philadelphia, 2Cell
Biology, Yale University, New Haven, United States |
|
| 17:05 |
P008-M |
DIPHYLLIN, A NOVEL POTENT V-ATPASE INHIBITOR,
ABROGATES ACIDIFICATION OF THE OSTEOCLASTIC RESORPTION LACUNAE AND
BONE RESORPTION
M. G. Sørensen*1, K. Henriksen1, A. V. Neutzsky-Wulff1, C.
Christiansen2, M. A. Karsdal1
1Pharmacology, Nordic Bioscience, 2Center for Clinical and Basic Research,
Herlev, Denmark
|
|
| 17:10 |
P009-T |
APPLICATION OF BIOLUMINESCENCE IN BONE
FORMATION
K. E. De Rooij*1, G. van der Horst1, H. Sips1, I. Que1, L. van der
Wee-Pals1, J. Hoogendam2, C. W. G. M. Löwik1, M. Karperien1
1Endocrinology, 2Pediatrics, Leiden University Medical Center, Leiden,
Netherlands |
|
| 17:15 |
P010-S |
HIGH-THROUGHPUT GENETIC EXPRESSION PROFILES
AND PROTEOMICS APPROACHES FOR UNDERSTANDING THE BISPHOSPHONATE'S MODES
OF ACTION ON BONE
N. Bivi*1, P. Picotti2, J. Berezsczak3, M. Romanello1, F. Brancia3,
D. Delneri4, G. Tell1, L. Moro5
1Department of Biomedical Sciences and Technologies, University of
Udine, Udine, Italy, 2Institute of Molecular Systems Biology, ETH
Honggerberg, Zurich, Switzerland, 3Shimadzu Research Laboratories,
Shimadzu Corp., 4Faculty of Life Sciences, University of Manchester,
Manchester, United Kingdom, 5Department of Biochemistry, Centre for
the Study of Metabolic Bone Diseases, University of Trieste, Trieste,
Italy |
|
16:30-
17:30 |
|
Short
Oral Communications 1: CLINICAL
Chairs: Nina Bjarnason (Hellerup, Denmark)
Larry Raisz (Farmington, USA)
|
|
|
| 16:30 |
P021-T |
SRP3 AND SRP9 POLYMORPHISMS IN THE SOST GENE ARE ASSOCIATED
WITH
PERIMENOPAUSAL BONE MASS AND EARLY POSTMENOPAUSAL BONE LOSS
N. González-Bofill*1, L. B. Husted1, P. Vestergaard1, C. L.
Tofteng2, B. Abrahamsen3, P. Eiken4, B. L. Langdahl1
1Department of Endocrinology, Aarhus Hospital, Aarhus, 2Department
of Endocrinology, Hvidovre Hospital, Hvidovre, 3Department of Endocrinology,
Roskilde County Hospital, Roskilde, 4Department of Endocrinology,
Hillerød Hospital, Hillerød, Denmark |
|
| 16:35 |
P022-S |
NO EVIDENCE OF ASSOCIATION BETWEEN CODING LRP5/6 POLYMORPHISMS
AND BMD AND FRACTURE RISK IN THREE INDEPENDENT LARGE-SCALE POPULATION
BASED STUDIES OF YOUNG AND ELDERLY MEN
E. Grundberg*1, M. Lorentzson2, E. M. Lau3, M. Karlsson4, D. Mellström2,
A. Holmberg4, E. Orwoll5, H. Mallmin6, C. Ohlsson2, Ö. Ljunggren1,
K. Åkesson4
1Department of Medical Sciences, Uppsala University Hospital, Uppsala,
2Department of Internal Medicine, Center for Bone Research at the
Sahlgrenska Academy, Göteborg, Sweden, 3Hong Kong Orthopaedic
and Osteoporosis Center for Treatment and Research, Hong Kong, China,
4Department of Orthopaedics, Malmö University Hospital, Malmö,
Sweden, 5Department of Medicine, Bone and Mineral Research Unit at
Oregon Health and Science University, Portland, United States, 6Deparment
of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden |
|
| 16:40 |
P023-M |
VARIATIONS IN THE LRP5 AND LRP6 GENES: ASSOCIATIONS
WITH BONE MINERAL DENSITY IN SCOTTISH POSTMENOPAUSAL WOMEN
C. A. Parsons*1, H. M. Macdonald1, F. E. McGuigan2, A. Stewart1, S.
H. Ralston3, D. M. Reid1
1Medicine and Therapeutics, University of Aberdeen Medical School,
Aberdeen, United Kingdom, 2Department of Orthopedics, Malmö University
Hospital, Malmö, Sweden, 3Molecular Medicine Centre, Western
General Hospital, Edinburgh, United Kingdom |
|
| 16:45 |
P024-T |
VARIATION IN THE BONE MORPHOGENETIC PROTEIN 2 GENE:
BODY COMPOSITION AND BONE MINERAL DENSITY IN YOUNG AND ELDERLY WOMEN
F. E. A. McGuigan*1, E. Larzenius2, M. Callreus2, L. Jansson2, P.
Gerdhem2, H. Luthman3, K. Åkesson2
1Department of Orthopedics, 2Department of Orthopedics, 3Department
of Medical Genetics, Lund University, Malmö, Sweden |
|
| 16:50 |
P025-S |
IDENTIFICATION OF SEX-SPECIFIC EFFECTS
OF TNFRSF11B POLYMORPHISMS ON THE RISK TO DEVELOP PAGET'S DISEASE
OF BONE
G. Beyens*1, A. Daroszewska2, F. de Freitas1, E. Fransen1, F. Vanhoenacker3,
L. Verbruggen4, H. G. Zmierczak5, S. H. Ralston2, J. P. Devolgelaer6,
W. Van Hul1
1Medical Genetics, University and University Hospital of Antwerp,
Antwerp, Belgium, 2Molecular Medicine Centre, Western General Hospital,
Edinburgh, United Kingdom, 3Radiology, University Hospital of Antwerp,
Antwerp, 4Rheumatology, University Hospital of Brussels, Brussels,
5Endocrinology and Metabolic Diseases, University Hospital of Ghent,
Ghent, 6Rheumatology, Saint-Luc University Hospital, Brussels, Belgium
|
|
| 16:55 |
P026-M |
THIGH MUSCLE AREA CORRELATES WITH BONE MINERAL DENSITY
(BMD) IN HEALTHY MEN AT THE TIME OF PEAK BONE MASS-RESULTS FROM THE
ODENSE ANDROGEN STUDY
L. Frederiksen*1, T. L. Nielsen1, K. Wraae1, C. Hagen1, M. Andersen1,
K. Brixen1
1Endocrinology, Odense University Hospital, Odense, Denmark |
|
| 17:00 |
P027-T |
ADIPONECTIN IS A PREDICTOR OF PEAK BONE MASS IN MEN
M. F. Nielsen*1, B. Abrahamsen2, T. Nielsen1, M. Andersen1, C. Hagen2,
K. Brixen1
1Dept. of Endocrinology, Odense University Hospital, Odense, 2Dept.
of Endocrinology, Gentofte County Hospital, Copenhagen, Denmark |
|
| 17:05 |
P028-S |
INTRINSIC BONE QUALITY IN FRAGILITY HIP FRACTURE PATIENTS:
ALTERED
MINERALISATION AND MICRODAMAGE ACCUMULATION
J. S. Kuliwaba*1, P. Sutton-Smith1, N. L. Fazzalari1
1Division of Tissue Pathology, Institute of Medical and Veterinary
Science, Discipline of Pathology, The University of Adelaide, Adelaide,
Australia |
|
| 17:10 |
P029-M |
PARATHYROID HORMONE IS AN INDEPENDENT
PREDICTOR OF FIBROBLAST GROWTH FACTOR-23 IN HEALTHY MEN: MROS SWEDEN
R. Marsell*1, E. Grundberg2, T. Krajisnik2, P. Westerberg2, H. Mallmin1,
M. Karlsson3, D. Mellström4, E. Orwoll5, C. Ohlsson4, K. B. Jonsson1,
Ö. Ljunggren2, T. Larsson2
1Dep. of Surgical Sciences, 2Dep. of Medical Sciences, Uppsala University
Hospital, Uppsala, 3Clinical and Molecular Osteoporosis Research Unit,
Department of Clinical Sciences, Department of Or, Malmö University
Hospital, Malmö, 4Department of Internal Medicine, Sahlgrenska
University Hospital, Gothenburg, Sweden, 5Oregon Health & Science
University, Oregon Health & Science University, Portland, United
States |
|
| 17:15 |
P030-T |
BLOOD LEAD LEVELS, RATES OF BONE LOSS
AND INCIDENT FRACTURES: THE STUDY OF OSTEOPOROTIC FRACTURES (SOF)
J. A. Cauley*1, N. Khalil1, E. O. Talbott1, J. W. Wilson2, S. B. Muldoon3,
L. Morrow4, M. C. Hochberg5, T. A. Hillier6, S. R. Cummings7
1Epidemiology, 2Biostatistics, University of Pittsburgh, Pgh, 3Epidemiology,
University of Louisville, Louisville, KY, 4Psychiatry, University
of Pittsburgh, Pgh, 5Medicine, University of Maryland Medical Center,
Baltimore, 6Medicine, Kaiser Permanente Center for Health Research,
Portland, OR, 7Medicine, San Francisco Coordinating Center, CPMC,
San Francisco, CA, United States |
|
| Tuesday 8 May, 2007 |
|
16:30-
17:30 |
|
Short
Oral Communications 2: BASIC
Chair: Moustapha Kassem (Odense, Denmark)
Wim Val Hul (Antwerp, Belgium) |
|
| 16:30 |
P011-M |
BONE-DERIVED LIPIDS STIMULATE BREAST CANCER
CELL GROWTH THROUGH A
CROSSTALK BETWEEN FARNESOID X RECEPTOR AND ESTROGEN RECEPTOR: IN VITRO
AND CLINICAL DATA
F. Journe*1, G. Laurent2, C. Chaboteaux1, D. Nonclercq2, V. Durbecq1,
D. Larsimont1, J. Body1
1Department of Internal Medicine, Institut Bordet, Brussels, 2Laboratory
of Histology, Université de Mons-Hainaut, Mons, Belgium |
|
| 16:35 |
P012-T |
ACCE LERATED BONE RESORPTION PROMOTES
TUMOUR GROWTH IN A MURINE MODEL OF BREAST CANCER BONE METASTASIS
Y. Zheng1, H. Zhou1, J. R. K. Modzelewski1, R. Kalak1, J. M. Blair1,
M. J. Seibel*1, C. R. Dunstan1
1Bone Research Program, ANZAC Research Institute, University of Sydney
Concord RG Hospital, Sydney, Australia |
|
| 16:40 |
P013-S |
ZOLEDRONIC ACID RESISTANCE MECHANISMS
OF OSTEOSARCOMA CELL LINES
B. Ory*1, G. Moriceau1, F. Rédini1, M. Rogers2, D. Heymann1
1LPRO, ERI 7, Nantes, France, 2Bone Research Group, Institute of Medical
Sciences, Aberdeen, United Kingdom |
|
| 16:45 |
P014-M |
THE PPAR GAMMA AGONIST PIOGLITAZONE EXAGGERATES
BONE LOSS, WHILE THE PPAR ALPHA AGONIST FENOFIBRATE MAINTAINS BMD
AND BONE ARCHITECTURE IN OVARECTOMIZED RATS
A. K. Stunes*1, B. Gustafsson2, R. Berge3, I. Westbroek4, J. E. Reseland5,
U. Syversen1
1Dept of Cancer Research and Mol. Medicine, Norwegian University of
Science and Technology, 2Dept of Gastroenterology, St Olav’s
University Hospital HF, Trondheim, 3Section of Medical Biochemistry,
Institute of Medicine, University of Bergen, Bergen, Norway, 4Internal
Medicine and Orthopaedics, Erasmus MC, Rotterdam, Netherlands, 5Dept
of Biomaterials, Institute for Clinical Dentistry, University of Oslo,
Oslo, Norway |
|
| 16:50 |
P015-T |
SYSTEMIC ADMINISTRATION OF THYROID STIMULATING
HORMONE (TSH) RESTORES BONE VOLUME AND STRENGTH WITHOUT AFFECTING
SERUM T3 AND T4 LEVELS IN AGED OVARIECTOMIZED RATS
R. Sendak*1, M. Huff1, K. Culm-Merdek1, S. Schiavi1, J. M. McPherson1,
P. Simic2, S.Vukicevic2, K. T. Sampath1
1Research and Development, Genzyme Corporation, Framingham, United
States, 2Department of Anatomy, Medical School, Zagreb, Croatia |
|
| 16:55 |
P016-S |
THE ACTIVIN A – FOLLISTATIN SYSTEM:
POTENT REGULATOR OF EXTRACELLULAR MATRIX SYNTHESIS AND MINERALIZATION
M. Eijken*1, S. Swagemakers2, M. Koedam1, C. Steenbergen1, P. Derkx1,
A. G. Uitterlinden1, P. J. van der Spek2, J. A. Visser1, F. H. de
Jong1, H. A. P. Pols1, J. P. T. van Leeuwen1
1Department of Internal Medicine, 2Department of Bioinformatics,
ErasmusMC, Rotterdam, Netherlands
|
|
| 17:00 |
P017-M |
ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR
AND ITS RECEPTORS AS
MEDIATORS OF VARIOUS PROFIBROGENIC ACTIONS OF PARATHYROID HORMONE-RELATED
PROTEIN IN THE KIDNEY
J. A. Ardura*1, R. Berruguete1, D. Rámila1, M. V. Alvarez-Arroyo1,
P. Esbrit1
1Bone and Mineral Metabolism Laboratory, Fundación Jiménez
Díaz Capio Group, Madrid, Spain |
|
| 17:05 |
P018-T |
GONADAL ANDROGENS AND PERIPHERAL AROMATIZATION
AFFECT PERIOSTEAL BONE GROWTH IN MALE MICE DURING PUBERTY
F. Callewaert*1, K. Venken1, J. Ophoff1, S. Boonen1, R. Bouillon1,
D. Vanderschueren1
1Laboratory of Experimental Medicine and Endocrinology, KULeuven,
Leuven, Belgium |
|
| 17:10 |
P019-S |
KINETIC ANALYSIS OF CONFORMATIONAL CHANGES
IN FARNESYL PYROPHOSPHATE SYNTHASE INDUCED BY NITROGEN CONTAINING
BISPHOSPHONATES
J. E. Dunford*1, K. L. Kavanagh2, M. J. Rogers3, U. Oppermann2, F.
H. Ebetino4, G. Russell1
1Nuffield Department of Orthopaedic Surgery, 2Structural Genomics
Consortium, Oxford University, Oxford, 3Bone Research Group, Aberdeen
University, Aberdeen, United Kingdom, 4New Drug Development, Proctor
and Gamble, Mason, OH, United States |
|
| 17:15 |
P020-M |
STRONTIUM RANELATE COUNTERACTS THE DRAMATIC
INCREASE OF ENDOCORTICAL RESORPTION IN MICE WITH A SEVERE OSTEOPOROSIS
V. Geoffroy*1, D. Chappard2, H. Libouban2, F. Pascaretti2, A. Ostertag1,
M. C. De Vernejoul1
1INSERM U606, Hospital Lariboisiere, Paris, 2EMI 0335, INSERM, Angers,
France |
|
16:30-
17:30
|
|
Short
Oral Communications 2: CLINICAL
Chairs: Steven Boonen (Liège, Belgium)
Lars Hyldstrup (Hvidovre, Denmark) |
|
| 16:30 |
P031-S |
EFFECT OF ONCE-YEARLY INFUSION OF ZOLEDRONIC
ACID 5 MG IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
D. Black1, P. D. Delmas2, R. Eastell3, I. Reid4, S. Boonen5, J. A.
Cauley6, P. Lakatos7, P. C. Leung8, Z. Man9, E. F. Eriksen10, P. Mesenbrink11,
T. Hue1, B. Langdahl*12, S. Cummings13
1Department of Epidemiology and Biostatistics, University of California,
San Francisco, San Francisco, United States, 2Department of Medicine,
University Claude Bernard of Lyon, Lyon, France, 3Metabolic Bone Centrer,
Northern General Hospital, Sheffield, United Kingdom, 4Faculty of
Medicine and Health Sciences, Auckland University, Auckland, New Zealand,
5Center for Metabolic Bone Diseases, Leuven University, Leuven, Belgium,
6Department of Epidemiology, University of Pittsburgh, Pittsburgh,
United States, 7Department of Medicine, Semmelweis University, Budapest,
Hungary, 8Department of Medicine, Chinese University of Hong Kong,
Shatin, Hong Kong Special Administrative Region of China, 9Department
of Medicine, Cnetro TIEMPO, Buenos Aires, Argentina, 10Department
of Medicine, Novartis Pharma AG, Basel, Switzerland, 11Biostatistics,
Novartis Pharmaceuticals Corporation, East Hanover, United States,
12Department of Medicine, University of Aarhus, Aarhus, Denmark, 13Department
of Medicine, University of California, San Francisco, San Francisco,
United States |
|
| 16:35 |
P032-M |
HISTOMORPHOMETRIC AND MICRO-CT ANALYSIS
OF BONE BIOPSIES AFTER 3 ANNUAL INFUSIONS OF ZOLEDRONIC ACID 5 MG:
EVIDENCE FOR PRESERVATION OF BONE STRUCTURE AND REMODELING CAPACITY
R. R. Recker1, P. D. Delmas2, I. Reid3, S. R. Boonen4, J. Halse5,
J. Supronik6, P. Garcia7, F. Hartl8, P. Mesenbrink9, J. Gasser10,
E. F. Eriksen*8
1Department of Endocrinology, Creighton University School of Medicine,
Omaha, United States, 2Department of Medicine, University Claude Bernard
of Lyon, Lyon, France, 3Faculty of Medicine and Health Sciences, Auckland
University, Auckland, New Zealand, 4Center for Metabolic Bone Diseases,
Leuven University, Leuven, Belgium, 5Betanien Medical Laboratory,
Betanien Medical Center, Oslo, Norway, 6Department of Medicine, Sniadecki
Hospital, Bialystok, Poland, 7Department of Medicine, Universitario
de Monterrey, Monterrey, Mexico, 8Department of Medicine, Novartis
Pharma AG, Basel, Switzerland, 9Biostatistics, Novartis Pharmaceuticals
Corporation, East Hanover, United States, 10Department of Medicine,
Novartis Institutes for BioMedical Research, Basel, Switzerland |
|
| 16:40 |
P033-T |
IBANDRONATE-INDUCED REDUCTION OF BONE
TURNOVER MARKER PREDICTS
ANTIFRACTURE EFFICACY
P. D. Miller*1, R. Blackburn2, R. Grant3, R. R. Recker4
1Department of Medicine, Colorado Center for Bone Research, Lakewood,
United States, 2Pharma-Development Medical Biostatistics, Roche Products
Ltd, Welwyn Garden City, United Kingdom, 3Inflammatory and Bone Diseases,
Hoffmann-La Roche Inc., Nutley, 4Osteoporosis Research Center, Creighton
University, Omaha, United States |
|
| 16:45 |
P034-S |
IBANDRONATE-INDUCED BONE MINERAL DENSITY
GAINS ARE RELATED TO
VERTEBRAL ANTIFRACTURE EFFICACY
S. Adami*1, P. D. Miller2, K. M. Patel3, R. C. Schimmer4, R. Grant5,
R. R. Recker6
1Department of Rheumatology, University of Verona, Verona, Italy,
2Department of Medicine, Colorado Center for Bone Research, Lakewood,
United States, 3PDMB, 4Medical Science, F. Hoffmann-La Roche Ltd,
Basel, Switzerland, 5Inflammatory and Bone Diseases, Hoffmann-La Roche
Inc., Nutley, 6Osteoporosis Research Center, Creighton University,
Omaha, United States
|
|
| 16:50 |
P035-M |
EFFICACY AND SAFETY OF A NOVEL TRANSDERMAL
LOW-DOSE ESTRADIOL DELIVERY SYSTEM (MENOSTAR) FOR THE PREVENTION OF
POSTMENOPAUSAL BONE LOSS COMPARED WITH RALOXIFENE (EVISTA): A 2-YEAR
RADOMIZED CLINICAL TRIAL
L. B. Tankó*1, M. Schäfers2, C. Muysers2, C. Christiansen1
1Clinical Research, Center for Clinical and Basic Research, Ballerup,
Denmark, 2Gynecology, Schering AG, Berlin, Germany |
|
| 16:55 |
P036-T |
STRONTIUM RANELATE DEMONSTRATES VERTEBRAL
AND NON-VERTEBRAL ANTI FRACTURE EFFICACY INCLUDING HIP FRACTURES OVER
5 YEARS IN POST MENOPAUSAL OSTEOPOROTIC WOMEN
J. Y. Reginster*1, K. Brixen2, C. Cormier3, J. Cannata4
1Unité d'Exploration du Métabolisme Osseux, CHU BRULL,
Liège, Belgium, 2Endocrinology, Odense University Hospital,
Odense, Denmark, 3Rheumatology A Department, Cochin Hospital Paris
V University, Paris, France, 4Servicio de Metabolismo Oseo y Mineral,
Hospital Central de Asturias, Oviedo, Spain |
|
| 17:00 |
P037-S |
BONE MINERAL DENSITY RESPONSE TO 24 MONTHS
OF TERIPARATIDE (RHPTH 1-34) IN PATIENTS WITH INADEQUATE RESPONSE
TO PRIOR ANTIRESORPTIVE TREATMENT
K. Brixen*1, T. N. Nickelsen2, F. Marin3, C. Barker4, B. Obermayer
- Pietsch5, C. C. Glueer6, J. Farrerons7, M. Audran8, S. Boonen9,
R. Eastell10
1Dept of Endocrinology, Universitetshospital, Odense, Denmark, 2Endocrine
Research, Eli Lilly and Company Europe, Bad Homburg, Germany, 3Endocrine
Research, Eli Lilly and Company Europe, Madrid, Spain, 4Dept. of Biostatistics,
Eli Lilly and Company Europe, Windlesham, United Kingdom, 5Dept of
Endocrinology, Med. Universitaetsklinik, Graz, Austria, 6Klinik Fuer
Diagnostische Radiologie, UKSH, Kiel, Germany, 7Consultas Medicina
Interna, Hospital Santa Creu I Sant Pau, Barcelona, Spain, 8Service
de Rhumatologie, Faculté de Médecine, Angers, France,
9Dept of Pathophysiology, University of Leuven, Leuven, Belgium, 10Metabolic
Bone Centre, University of Sheffield, Sheffield, United Kingdom |
|
| 17:05 |
P038-M |
TERIPARATIDE REDUCES THE RISK FOR NEW
ADJACENT VERTEBRAL FRACTURES
M. L. Bouxsein*1, P. Chen2, E. V. Glass2, D. F. Kallmes3, B. H. Mitlak2
1Orthopedic Biomechanics Laboratory, Beth Israel Deaconess Medical
Center and Harvard Medical School, Boston, 2Lilly Research Labs, Eli
Lilly and Company, Indianapolis, 3Radiology, Mayo Clinic, Rochester,
United States |
|
| 17:10 |
P039-T |
EFFICACY OF PTH (1-84) ON VERTEBRAL AND
NON-VERTEBRAL FRACTURES IN
POSTMENOPAUSAL WOMEN WITH A HIGH RISK OF VERTEBRAL FRACTURES
C. Roux*1, O. Illera Martín2, J. Clausen3
1CHU Cochin, Service Rhumatologie, Paris, France, 2Servicio de Reumatología,
Hospital Ramón y Cajal, Madrid, Spain, 3International Medical
Affairs, Nycomed, Roskilde, Denmark |
|
| 17:15 |
P040-S |
THE INFLUENCE OF A ONE-YEAR MODERATE INTENSITY
SCHOOL-BASED PHYSICAL ACTIVITY PROGRAM ON BONE DENSITY, MUSCLE STRENGTH,
BODY COMPOSITION AND PHYSICAL PERFORMANCE IN PRE-PUBERTAL GIRLS –DATA
FROM THE PEDIATRIC OSTEOPOROSIS PREVENTION (POP) STUDY
S. Stenevi-Lundgren*1, R. M. Daly2, C. Linden1, M. K. Karlsson1
1Clinical and Molecular Osteoporosis Research Unit, Department of
Clinical Sciences, Lund University, Malmö University Hospital,
Malmo, Sweden, 2Centre for Physical Activity and Nutrition Research,
School of Exercise and Nutrition Sciences, Deakin University, Melbourne,
Australia |
|
Scientific
Programme Meet
the Professor Allied
Health Professionals Session
Other Events Speaker Biographies Call for Abstracts Awards
& Grants
CPD/CME
Committees Reviewers
Information for Presenters
|
|
|
